Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BIO-THERA SOLUTIONS, LTD. holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 5 pending office actions, which are distributed among 5 distinct examiners. This indicates a highly diversified prosecution environment where every active matter is being reviewed by a different person. The presence of 5 distinct art units further suggests that the company's intellectual property spans five separate technical specializations within the biotechnology sector, requiring a broad strategic approach.
The busiest examiner for this portfolio is CANELLA, KAREN A, who is responsible for 1 pending office action. Since the total number of pending office actions is 5, the workload is perfectly divided among the 5 distinct examiners. This lack of concentration means that no single examiner has a controlling influence over the portfolio's progress. Practitioners must manage 5 independent prosecution timelines and adapt to the specific preferences of each examiner, as the 1 pending action per examiner ensures a balanced workload.
The ratio of 5 distinct examiners to 5 distinct art units implies that each examiner is likely focused on a unique technical area. This structure requires a broad legal strategy to ensure that the 5 pending office actions are handled consistently across the different art units. The busiest examiner's load of 1 pending action reflects the even distribution of the total workload. This decentralized arrangement places a premium on maintaining a unified voice across the various interactions with the patent office to protect the company's diverse intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (60%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| LU, CHENG | 1 | 53.8% | +64.6% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701217 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | CANELLA, KAREN A | — |
| 18275747 | ANTI-IL-5 ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF | BENAVIDES, JENNIFER ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701217 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | CANELLA, KAREN A | — |
| 18697291 | ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF | LU, CHENG | — |
| 18681485 | USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES | CUNNINGCHEN, KATHLEEN MARY | — |
| 18275747 | ANTI-IL-5 ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF | BENAVIDES, JENNIFER ANN | — |
| 18035591 | BISPECIFIC ANTIBODY AND USE THEREOF | STOICA, ELLY GERALD | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1642 | 1 |
| 1646 | 1 |
| 1675 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701217 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | CANELLA, KAREN A | 1643 | §102§112Other | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18697291 | ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF | LU, CHENG | 1642 | §112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18681485 | USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112DP | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18275747 | ANTI-IL-5 ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §103§112 | Final Rejection | — | Pending | Aug 03, 2023 |
| 18035591 | BISPECIFIC ANTIBODY AND USE THEREOF | STOICA, ELLY GERALD | 1647 | §112DP | Non-Final OA | — | Pending | May 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIO-THERA SOLUTIONS, LTD. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Karen A Canella has the most, with 1 of BIO-THERA SOLUTIONS, LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
